Chronic myelogenous leukemia (CML) is caused by gene mutation on human chromosomes 9 and 22. This September 22 is the 11th World CML Day. Hansoh Pharma, in conjunction with Huilan Foundation, joined hands with nearly 20 hospitals in more than 10 cities across the country to jointly launch the "Being Cured · CML" campaign to provide health education and assistance services for CML patients in China.

The campaign aimed to arouse the public's attention to CML, so as to improve the awareness of the disease, enable standardized treatment and monitoring of patients, and ultimately improve the quality of life of patients. Medical experts were invited to share with patients the latest advances in CML treatment and methods of self-management of the disease, which enhanced patients' confidence in fighting the disease and played a positive role in the development and dissemination of disease diagnosis and treatment techniques and the enhancement of standardized diagnosis and treatment.

Hansoh Pharma joined hands with medical institutions to launch the "World CML Day" patient education campaign

CML was once an incurable disease; today, through standardized treatment and regular monitoring, CML has become a treatable and controllable chronic disease. More and more medical practice has confirmed that, after a period of standardized tyrosine kinase inhibitor (TKI) treatment, patients still have the ability to maintain deep molecular response (DMR), and can obtain long-term treatment free remission (TFR) and achieve clinical "cure".

Hansoh Pharma has been committed to improving drug accessibility and bringing better disease solutions to patients. In 2013, with its unique scientific and technological innovation and key breakthrough technology, Hansoh Pharma launched the first generic of first-generation TKI Xinwei (Imatinib Mesylate Tablets), which greatly improved the accessibility and affordability of medication. Because of its excellent efficacy and significant price advantage, imatinib was included in the national reimbursement drug list in 2017. In 2018, Xinwei became the first to pass the generic drug consistency evaluation and voluntarily reduce the price, which allowed more patients' access to the life-saving drug.

But this did not stop Hansoh Pharma researchers from exploring the treatment of CML. With the effective control of CML and the prolongation of patients' overall survival, more and more patients are eager for a higher quality of life, and drug withdrawal and "being cured" have become a higher goal for them.

After more than 10 years' investment, China's first independently developed "second-generation+" TKI Hansoh Xinfu (Flumatinib Mesylate Tablets) was approved for marketing in November 2019, with "bidirectional optimization" in efficacy and safety. Only half a year later, in May 2020, Hansoh Xinfu was included in the first-line treatment by the Guidelines for Diagnosis and Treatment of Chronic Myeloid Leukemia in China (2020 Edition), which means that newly diagnosed CML patients can directly receive the drug treatment, thus achieving deep molecular remission faster; patients' long-pursuit goal of "being cured" is now possible.

Hansoh Xinfu (Flumatinib Mesylate Tablets)

In July this year, Hansoh Pharma signed a strategic cooperation agreement with Terns Pharmaceuticals, a global innovative pharmaceutical company, to introduce TRN-000632, a highly active BCR-ABL protein allosteric inhibitor that is being used to develop CML-related indications, into China, which has accelerated the pace of action to help domestic CML patients and brought more treatment options to patients.

Hansoh Pharma，Escorts Every CML Patient on the Way to Being Cured!